Advantages to using surrogate vs clinical end points in drug approvals include earlier access, but there can be concerns about the efficacy and end result of the drug, said Yuqian Liu, PharmD, senior director of specialty clinical solutions at Magellan Rx Management.
At AMCP 2023, Yuqian Liu, PharmD, senior director of specialty clinical solutions at Magellan Rx Management, explains how using surrogate vs clinical outcomes data can influence a drug's time to market, and how drugs approved through the accelerated pathway affect formulary management differently based on the line of business.
Transcript
How do surrogate end points differ from clinical end points, and what are some pros and cons of using them in the accelerated drug approval process?
A surrogate end point is a predictor of clinical outcome, whereas an actual clinical end point is the outcome itself. So it's a metric of outcome, and that's the main difference between a surrogate end point and a clinical end point. From a patient perspective, now the use of a surrogate end point does allow you to bring the drug to market a lot sooner. So the predictor doesn't require the full scope and the spectrum of time to be able to achieve that end result, what the end result does. So from a patient perspective, they'll be able to see the accelerated approvals come to market a lot quicker through use of a surrogate end point.
However, from a payer perspective, it is very good that we're supporting the patient, but at the same time we are concerned about whether or not the surrogate end points can truly predict the end result. Because, like I said before, it’s not a true metric. From a payer perspective, we’re also very concerned about the safety and ultimately whether or not the drug works for the patient. So there are some pros and cons to both—earlier access to the drug, but at the same time, you have to worry about the efficacy and the end result of the product.
How do drugs approved through the accelerated approval pathway affect formulary management?
It's different based on the line of business. So Medicare obviously have their own regulations regarding how to provide coverage for the accelerated approval products. They have an NCD [national coverage determination] that will only cover the accelerated approvals when it's used in an approved trial. Now, Medicaid are state regulated, so the individual states have their way to regulate accelerated approvals. And then, for the commercial population, usually that's a decision on a health plan basis, so then the individual health plan gets to assess, based on the clinical efficacy data available at the time, whether or not a drug should be covered on their formulary or not.
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More